Fischer Medical board to consider Q4FY26 results on May 29
Fischer Medical Ventures Limited will hold a board meeting on May 29, 2026, via video conferencing. The board will consider the audited financial results for the quarter and year ended March 31, 2026, and may recommend a dividend. The trading window for designated persons remains closed until 48 hours post-results declaration.

*this image is generated using AI for illustrative purposes only.
fischer medical ventures has scheduled a meeting of its Board of Directors for Friday, May 29, 2026. The meeting will be held via video conferencing to discuss key financial matters and business items.
Agenda for the Meeting
The primary agenda for the board meeting includes the consideration and approval of the audited standalone and consolidated financial results of the company for the quarter and year ended March 31, 2026. Additionally, the directors will evaluate and potentially recommend a dividend for the period, subject to the board's discretion and financial performance.
Trading Window Closure
In compliance with regulatory standards, the company has informed the exchanges that the trading window for dealing in the equity shares of Fischer Medical Ventures Limited is currently closed. This restriction applies to all designated persons, their immediate relatives, and other connected persons. The window shall remain closed until the conclusion of 48 hours after the declaration of the financial results for the quarter and year ended March 31, 2026.
Regulatory Compliance
The intimation was sent to BSE Limited and the National Stock Exchange of India Ltd. in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was signed by Balaji Gandla, Company Secretary & Compliance Officer, on behalf of the company.
Historical Stock Returns for Fischer Medical Ventures
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.08% | +8.27% | +0.89% | -19.49% | -51.72% | -51.72% |
What dividend yield might Fischer Medical Ventures offer compared to its peers in the medical sector, and how could this influence retail investor sentiment?
How have Fischer Medical Ventures' revenue and profitability trends evolved over the past few fiscal years, and what growth trajectory might the FY2026 results reveal?
Could the board's dividend decision signal a shift in the company's capital allocation strategy, potentially impacting its future expansion or R&D investments?


































